Article Information
History
- December 5, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Matthew N. Wakeling1,
- Nick D. L. Owens1,
- Jessica R. Hopkinson1,
- Matthew B. Johnson1,
- Jayne A.L. Houghton2,
- Antonia Dastamani3,
- Christine S. Flaxman1,
- Rebecca C. Wyatt1,
- Thomas I. Hewat1,
- Jasmin J. Hopkins1,
- Thomas W. Laver1,
- Rachel Van Heugten2,
- Michael N. Weedon1,
- Elisa De Franco1,
- Kashyap A. Patel1,
- Sian Ellard2,
- Noel G. Morgan1,
- Edmund Cheesman4,
- Indraneel Banerjee5,6,
- Andrew T. Hattersley1,
- Mark J. Dunne6,
- International Congenital Hyperinsulinism Consortium,
- Sarah J. Richardson1 and
- Sarah E. Flanagan1,*
- 1Institute of Biomedical and Clinical Science, University of Exeter Medical School, UK
- 2Exeter Genomics Laboratory, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
- 3Endocrinology Department, Great Ormond Street Hospital for Children, London, UK
- 4Department of Paediatric Pathology, Royal Manchester Children’s Hospital, Oxford Road, Manchester, UK
- 5Department of Paediatric Endocrinology, Royal Manchester Children’s Hospital, Oxford Road, Manchester, UK
- 6Faculty of Biology, Medicine and Health, The University of Manchester, Oxford Road, Manchester, UK
- ↵*Corresponding author:
Dr Sarah E. Flanagan, Associate Professor in Genomic Medicine, RILD Building, University of Exeter Medical School, Barrack Road, Exeter, EX2 5DW, UK, S.Flanagan{at}exeter.ac.uk
Posted December 05, 2021.
A novel disease mechanism leading to the expression of a disallowed gene in the pancreatic beta-cell identified by non-coding, regulatory mutations controlling HK1
